Results of a retrospective study conducted in Spain found that dialectical-behavioral therapy skills training can help mitigate polypharmacy in those with borderline personality disorder.
New study findings indicate that a dialectical-behavioral therapy skills training (DBT-ST) module can benefit patients with borderline personality disorder (BPD) when it comes to the reduction of medication load, specifically sedatives.
BPD is a severe but common disorder and accounts for approximately 20% of psychiatric inpatient populations, researchers explained. The condition is associated with psychosocial and occupational dysfunctions and substantial economic burden. Although there are no drugs specifically approved for BPD, most patients only receive pharmacological treatment as access to psychological therapies is limited.
In addition, “the optimal therapeutic drug for BPD-specific symptoms is controversial, in part due to the scant research on pharmacological management in patients with BPD but also to the lack of consensus pharmacological recommendations in clinical guidelines for BPD,” authors wrote.
Medication use in BPD also carries risks for these patients including addiction potential, serious adverse effects, and a high risk for self-injury. Meanwhile, DBT serves as one of the most effective psychotherapeutic treatments for BDP as it helps patients develop cognitive-behavioral principles to replace maladaptive behaviors with healthier coping skills, authors wrote.
DBT-ST encompasses 4 modules focused on mindfulness, distress tolerance, interpersonal effectiveness, and emotion regulation, researchers said. Offering the therapy to patients does not rule out the use of accompanying medications. Importantly, one of the aims of DBT-ST is to taper medication use while increasing the use and proficiency of the module’s trained skills.
In an effort to determine whether use of DBT-ST actually does reduce the use of medications and/or polypharmacy in those with BPD, investigators retrospectively collected and assessed data from 377 patients receiving outpatient care at a single center in Spain between 2010 and 2020.
All individuals included in the study had confirmed diagnoses of BPD, were between ages 18 and 55 years, and had no other neurological diseases or intellectual abilities that could affect psychotherapeutic intervention.
Participants were divided into 2 cohorts: those who elected to undergo DBT-ST (n = 182) and those who did not participate in the intervention (n = 195). “All patients received periodic psychiatric evaluation and follow-up visits, including supervision of pharmacological treatment to prevent excessive use of medications,” authors wrote.
Upon program admission:
Patients in the DBT-ST group also had greater clinical severity of BPD at the beginning of the study and were taking more medications on average compared with controls.
The rates of patients with BPD taking at least 1 medication and experiencing polypharmacy were similar to those seen in previous studies.
“This prescription practice in the public mental health system in Spain is consistent with clinical practice in other western countries and higher than recommended in some clinical guidelines (eg, United Kingdom and Australian guidelines), which do not recommend prescribing pharmacological agents to treat BPD symptoms, but only to treat comorbid disorders or for short term use during periods of crisis,” researchers explained.
Previous research has also shown DBT-ST can help mediate reductions in suicide, depression, and anger. However, because DBT-ST is a resource-intensive treatment that requires specific clinical training, staffing, and time, it is not always available in public health systems, despite its promising potential, researchers wrote.
The retrospective, nonrandom nature of the study makes it susceptible to potential selection bias; a prospective, double-blind randomized clinical trial is warranted to confirm the current findings.
Researchers also cautioned that the observed decrease in medication “does not necessarily imply better functional outcomes.”
Overall, “findings support the value of a coordinated and synergistic approach between psychopharmacologic and psychotherapeutic interventions in BPD,” they concluded.
“Providing patients with tools to effectively manage distress could reduce the need for these patients to resort to the use of pharmaceuticals as their main approach to reducing distress,” they said.
Soler J, Casellas-Pujol E, Fernández-Felipe I, Martín-Blanco A, Almenta D, Pascual JC. “Skills for pills”: the dialectical-behavioral therapy skills training module reduces polypharmacy in borderline personality disorder. Acta Psychiatr Scand. Published online January 27, 2022. doi:10.1111/acps.13403